Tweet
Vaccine. 2014 Mar 10. pii: S0264-410X(14)00305-3. doi: 10.1016/j.vaccine.2014.02.078. [Epub ahead of print]
Immunogenicity and safety of a trivalent inactivated 2010-2011 influenza vaccine in Taiwan infants aged 6-12 months.
Hwang KP1, Hsu YL2, Hsieh TH2, Lin HC2, Yen TY2, Wei HM2, Lin HC3, Chen AC4, Chow JC5, Huang LM6.
Author information
Abstract
This prospective study aimed to investigate the immune responses and safety of an influenza vaccine in vaccine-na?ve infants aged 6-12 months, and was conducted from November 2010 to May 2011. Fifty-nine infants aged 6-12 months received two doses of trivalent inactivated influenza vaccine 4 weeks apart. Hemagglutination inhibition titers were measured 4 weeks after the two doses of study vaccine. Based on the assumption that a hemagglutination inhibition titer of 1:40 or greater against the antigen would be protective in adults, two doses of the study vaccine generated a protective immune response of 63.2% against influenza A(H1N1), 82.5% against influenza A(H3N2) and 38.6% against influenza B viruses in infants aged 6-12 months. The geometric mean fold rises against influenza type A and B viruses also met the European Medicines Agency criteria for flu vaccines. The solicited events within 7 days after vaccination were mild in intensity. No deaths or adverse events such as optic neuritis, cranial neuropathy, and brachial neuropathy or Guillain-Barre syndrome were reported. Two doses of inactivated influenza vaccine were well tolerated and induced a protective immune response against influenza in infants aged 6-12 months.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Children, Immunogenicity, Infant, Influenza, Influenza vaccine, Safety
PMID:
24625341
[PubMed - as supplied by publisher]
Immunogenicity and safety of a trivalent inactivated 2010-2011 influenza vaccine in Taiwan infants aged 6-12 months.
Hwang KP1, Hsu YL2, Hsieh TH2, Lin HC2, Yen TY2, Wei HM2, Lin HC3, Chen AC4, Chow JC5, Huang LM6.
Author information
Abstract
This prospective study aimed to investigate the immune responses and safety of an influenza vaccine in vaccine-na?ve infants aged 6-12 months, and was conducted from November 2010 to May 2011. Fifty-nine infants aged 6-12 months received two doses of trivalent inactivated influenza vaccine 4 weeks apart. Hemagglutination inhibition titers were measured 4 weeks after the two doses of study vaccine. Based on the assumption that a hemagglutination inhibition titer of 1:40 or greater against the antigen would be protective in adults, two doses of the study vaccine generated a protective immune response of 63.2% against influenza A(H1N1), 82.5% against influenza A(H3N2) and 38.6% against influenza B viruses in infants aged 6-12 months. The geometric mean fold rises against influenza type A and B viruses also met the European Medicines Agency criteria for flu vaccines. The solicited events within 7 days after vaccination were mild in intensity. No deaths or adverse events such as optic neuritis, cranial neuropathy, and brachial neuropathy or Guillain-Barre syndrome were reported. Two doses of inactivated influenza vaccine were well tolerated and induced a protective immune response against influenza in infants aged 6-12 months.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Children, Immunogenicity, Infant, Influenza, Influenza vaccine, Safety
PMID:
24625341
[PubMed - as supplied by publisher]
